Video: Knock on Wood| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Lupus Nephritis
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Search results for: Biologics

Lupus Nephritis Therapies Compared, Plus Naming Guidance for Biosimilars

Michele B. Kaufman, PharmD, BCGP  |  September 9, 2015

Comparing tacrolimus, mycophenolate mofetil and cyclophosphamide, tacrolimus was the most efficacious. Also, biosimilars may soon be easier to differentiate…

Filed under:Biologics/DMARDsDrug Updates Tagged with:Biologics & BiosimilarscyclophosphamideFDAFood and Drug AdministrationLabeling ChangesLupus nephritismycophenolate mofetiltacrolimus

Arthritis May Be Worse in Poor Countries, but Seem Worse in Rich Ones

Janice Neumann  |  September 6, 2015

(Reuters Health)—A study of people with rheumatoid arthritis (RA) finds that those in wealthy nations are more troubled by it, even though people in poor countries have more severe symptoms. The results, tallied from 17 countries, suggest that cultural factors may influence patients’ perception of their illness, and possibly even the results of clinical trials…

Filed under:ConditionsRheumatoid Arthritis

Use Behavioral ‘Nudging’ to Tackle Gender, Health Challenges

Joseph D'Urso  |  September 4, 2015

LONDON (Thomson Reuters Foundation)—Many of the world’s biggest challenges, such as encouraging people to buy life-saving drugs or unpicking deeply rooted sexism, can be tackled by using subtle psychological cues to change the way people behave, according to experts in London. Behavioral economics, also known as “nudging,” is about making people more likely to make…

Filed under:Practice SupportProfessional TopicsWorkforce Tagged with:adherencemedication compliancepsychologicalpsychosocial

Novartis Launches First U.S. Biosimilar Drug at 15% Discount

Ben Hirschler & Michael Shields  |  September 4, 2015

LONDON/ZURICH (Reuters)—Novartis kicked off a new era in U.S. medicine on Thursday with the launch of the first biosimilar copy of a biotechnology drug approved in the U.S., at a discount of 15% to the original. The Swiss drugmaker’s generics unit Sandoz said Zarxio, its form of Amgen’s white blood cell-boosting product Neupogen (filgrastim), would…

Filed under:Biologics/DMARDsDrug Updates Tagged with:AmgenBiologics & BiosimilarsfilgrastimNovartis

FDA Warns of Severe Joint Pain Risk with DPP-4 Diabetes Drugs

Reuters Staff  |  August 31, 2015

(Reuters)—A class of diabetes drugs that include Merck & Co Inc.’s Januvia has been linked with severe joint pain, the U.S. Food and Drug Administration said on Friday. The FDA said it had identified 33 cases of severe joint pain in patients taking a class of drugs known as DPP-4 inhibitors between Oct. 16, 2006,…

Filed under:Drug Updates Tagged with:FDAjointJoint Pain

Early, Aggressive Therapy for RA May Result in Cost Savings Long Term

Lara C. Pullen, PhD  |  August 31, 2015

By considering the long-term damage from early, aggressive rheumatoid arthritis, researchers in the UK were able to develop a model demonstrating the long-term cost effectiveness of more aggressive combination therapies v. short-term treatments…

Filed under:ConditionsRheumatoid Arthritis Tagged with:adalimumabcombination therapyDisease-modifying antirheumatic drugs (DMARDs)healthcare costMethotrexateRheumatiod arthritis

FDA Proposes Adding Suffixes to Distinguish Biosimilar Drug Names

Toni Clarke  |  August 28, 2015

WASHINGTON (Reuters)—The U.S. Food and Drug Administration proposed on Thursday identifying cheaper versions of biologic drugs with a suffix to distinguish them from their more expensive, branded counterparts. The FDA said its draft guidance is designed to prevent the inadvertent substitution of non-interchangeable products and to make it easier to monitor and track usage once…

Filed under:Biologics/DMARDsDrug Updates Tagged with:Biologics & BiosimilarsdrugFDAFood and Drug AdministrationRegulation

Ustekinumab Found to Be Effective in Adolescents with Psoriasis

Rob Goodier  |  August 27, 2015

NEW YORK (Reuters Health)—Adolescents with moderate to severe psoriasis may respond to the human monoclonal antibody ustekinumab as well as adults, with no unexpected side effects, a new study found. The findings are exciting in part because patients in this age group have limited treatment options, the study’s lead author Dr. Ian Landells, of Memorial…

Filed under:Biologics/DMARDsDrug Updates Tagged with:AdolescentsPsoriasisustekinumab

Epratuzumab Results Disappointing, but Adalimumab Promising

Michele B. Kaufman, PharmD, BCGP  |  August 19, 2015

Two Phase 3 trials have shown that epratuzumab did not meet its primary endpoints for treating SLE. Meanwhile, a Phase 3 study has shown adalimumab is effective for treating enthesitis-related arthritis in juveniles…

Filed under:Biologics/DMARDsDrug Updates Tagged with:adalimumabenthesitis-related arthritisepratuzumabJuvenile arthritissystemic lupus erythematosus (SLE)

alphaspirit/shutterstock.com

Create a Physician Website that Conveys Authority, Expertise

Karen Appold  |  August 18, 2015

A website provides visitors with a first glimpse of your practice. “Whether you like it or not, people will learn about you and judge you based on your website,” says David Borenstein, MD, MACR, MACP, rheumatologist and partner, Arthritis and Rheumatism Associates, and clinical professor of medicine, Division of Rheumatology, Department of Medicine, The George…

Filed under:Practice SupportTechnology Tagged with:onlinephysicianTechnologywebsite

  • « Previous Page
  • 1
  • …
  • 55
  • 56
  • 57
  • 58
  • 59
  • …
  • 75
  • Next Page »
  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences